- Details
- Charles Ryan sits down with Rahul Aggarwal to discuss one of the first of its kind, the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic providing comprehensive care to men with prostate cancer who are receiving androgen deprivation therapy (ADT). While ADT is extremely effective, it causes side effects, including fatigue, hot flashes, and sexual changes, such as decreased libido (se...
|
- Details
- Alicia Morgans welcomes Michael Morris and Lawrence Schwartz to discuss the Prostate Cancer Working Group criteria as a refresher for investigators who are treating men with prostate cancer in clinical trials. Biographies: Michael J. Morris, MD., is the Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Ketteri...
|
- Details
- David Penson provides insights on his keynote lecture from ASCO GU 2020 in this conversation with Alicia Morgans. He focuses on recognizing that methods of effectively measuring a patient’s quality of life are not easy to define. In addition to the physical, psychological and social experiences that contribute to a patient’s quality of life, Dr. Penson argues the growing burden of financial resour...
|
- Details
- Susan Slovin joins Alicia Morgans to provide an update on the PRONOUNCE trial, the first Phase III prospective trial comparing a GnRH antagonist with a GnRH agonist with the endpoints of major adverse cardiovascular events. It explores how cardiovascular disease is not only affecting our patient's wellbeing on androgen deprivation therapy but also gives us for the first time a lot of different end...
|
- Details
- Christopher Logothetis and Charles Ryan review key takeaways from Christopher Logothetis's Advanced Prostate Cancer Consensus Conference (APCCC 2019) presentation on Ethnicity and Prognosis of Prostate Cancer and the importance in understanding the differences in outcomes of individuals with the disease based on race and ethnicity. In his work Dr. Logothetis prepared for APCCC 2019, he presses the...
|
- Details
- Matt Rettig discusses POPCaP and his work involving the health of veterans with prostate cancer and ongoing clinical trials going on exclusively within the Veterans Health Administration (VA) system. The Precision Oncology Program for Cancer of the Prostate (POPCaP), a partnership between the VA and the Prostate Cancer Foundation (PCF) to create a system of excellence for prostate cancer in VA is...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Joaquin Mateo, Principal Investigator, and Translational Scientist at the Vall d'Hebron hospital in Barcelona joined Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of t...
|
- Details
- Maria de Santis and Chuck Ryan share a conversation on the rapidly changing landscape for the treatment of locally advanced prostate cancer. A focus of the discussion centers around the STAMPEDE data demonstrating benefit with the early use of abiraterone and the use of radiation. They also discuss the role of docetaxel in this evolving environment based on data from both STAMPEDE and CHAARTED dat...
|
- Details
- Declan Murphy sits down with Alicia Morgans during the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to discuss men who have node positive but nonmetastatic prostate cancer and how we think about approaching treatment and integrating new imaging modalities into that entire therapeutic paradigm. Two aspects of managing node positive men in regards to surgery were talked about including...
|
- Details
- Alberto Bossi presented on the recommended treatment for men with pathological node-positive prostate cancer. These patients are becoming more common as surgery is being performed on a higher proportion of high-risk patients with positive nodes. Highlighting unanswered questions regarding the treatment of these patients following surgery, Dr. Alberto Bossi mentions several studies that have assess...
|
